These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27272089)

  • 1. Failure of Anakinra in a Case of Severe Hidradenitis Suppurativa.
    Russo V; Alikhan A
    J Drugs Dermatol; 2016 Jun; 15(6):772-4. PubMed ID: 27272089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.
    Tzanetakou V; Kanni T; Giatrakou S; Katoulis A; Papadavid E; Netea MG; Dinarello CA; van der Meer JWM; Rigopoulos D; Giamarellos-Bourboulis EJ
    JAMA Dermatol; 2016 Jan; 152(1):52-59. PubMed ID: 26579854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hidradenitis Suppurativa: Review of the Pathogenesis and Treatment.
    Kurayev A; Ashkar H; Saraiya A; Gottlieb AB
    J Drugs Dermatol; 2016 Aug; 15(8):1017-22. PubMed ID: 27538005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two cases of severe hidradenitis suppurativa with failure of anakinra therapy.
    Menis D; Maroñas-Jiménez L; Delgado-Marquez AM; Postigo-Llorente C; Vanaclocha-Sebastián F
    Br J Dermatol; 2015 Mar; 172(3):810-1. PubMed ID: 25059730
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term therapy with anakinra in hidradenitis suppurativa in three patients.
    André R; Marescassier H; Gabay C; Pittet B; Laffitte E
    Int J Dermatol; 2019 Nov; 58(11):e208-e209. PubMed ID: 31353451
    [No Abstract]   [Full Text] [Related]  

  • 8. Hidradenitis suppurativa in the pediatric population.
    Liy-Wong C; Pope E; Lara-Corrales I
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S36-41. PubMed ID: 26470613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report.
    van der Zee HH; Prens EP
    Dermatology; 2013; 226(2):97-100. PubMed ID: 23713053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hidradenitis suppurativa with biologic medications.
    Lee RA; Eisen DB
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
    Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
    Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hidradenitis suppurativa managed with adalimumab.
    Yamauchi PS; Mau N
    J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.
    Gottlieb A; Natsis NE; Kerdel F; Forman S; Gonzalez E; Jimenez G; Hernandez L; Kaffenberger J; Guido G; Lucas K; Montes D; Gold M; Babcock C; Simard J
    J Invest Dermatol; 2020 Aug; 140(8):1538-1545.e2. PubMed ID: 32004568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
    Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.
    Fardet L; Dupuy A; Kerob D; Levy A; Allez M; Begon E; Bachelez H; Morel P; Lebbé C
    J Am Acad Dermatol; 2007 Apr; 56(4):624-8. PubMed ID: 17240478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab for the treatment of hidradenitis suppurativa.
    Fernández-Vozmediano JM; Armario-Hita JC
    Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa.
    Boer J; Jemec GB
    Clin Exp Dermatol; 2010 Jan; 35(1):36-40. PubMed ID: 19549239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
    Gulliver WP; Jemec GB; Baker KA
    J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):911-4. PubMed ID: 21605174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.